Back to Search
LAUREN HUDAK, M.D., M.P.H.
M.D., M.P.H.
Emergency Medicine Physician
NPI: 1508127093IndividualAccepts Medicare
Education
EMORY UNIVERSITY SCHOOL OF MEDICINE
Class of 2012
Research & Publications (7)
Effects of combined valproic acid and the epidermal growth factor/vascular endothelial growth factor receptor tyrosine kinase inhibitor AEE788 on renal cell carcinoma cell lines in vitro.
PMID 19594733·BJU Int·2010
8-other
Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells.
PMID 19473483·BMC Cancer·2009
8-other
The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo.
PMID 18657224·J Cell Mol Med·2009
7-preclinical
Valproic acid blocks adhesion of renal cell carcinoma cells to endothelium and extracellular matrix.
PMID 19067765·J Cell Mol Med·2009
8-other
Modulation of adhesion and growth of colon and pancreatic cancer cells by the histone deacetylase inhibitor valproic acid.
PMID 18698487·Int J Mol Med·2008
8-other
[Preclinical studies on the influence of the tyrosine kinase inhibitor AEE788 on malignant properties of renal cell carcinoma cells].
PMID 18688594·Urologe A·2008
8-other
New histone deacetylase inhibitors as potential therapeutic tools for advanced prostate carcinoma.
PMID 18266964·J Cell Mol Med·2008
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Request Appointment
This provider isn't set up for online booking yet. Once you submit, we'll reach out to their office to arrange secure delivery of your request.
Contact & Hours
- Address
- 531 ASBURY CIR, SUITE N340
ATLANTA, GA 30322 - Phone
- (404) 778-5975
Quick Facts
- NPI
- 1508127093
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 14
- Publications
- 7
Are you this provider?
Claim Your Profile